Reuters logo
BRIEF-Ignyta's updated Phase 1 data on safety, anti-tumor activity published in Cancer Discovery
February 9, 2017 / 12:24 PM / 7 months ago

BRIEF-Ignyta's updated Phase 1 data on safety, anti-tumor activity published in Cancer Discovery

Feb 9 (Reuters) - Ignyta Inc

* Ignyta’s updated Phase 1 data on safety, anti-tumor activity and CNS activity of entrectinib in cancers with TRK, ROS1 or ALK fusions published in Cancer Discovery

* Ignyta Inc - updated results from two Phase 1 trials of entrectinib

* Ignyta - studies showed entrectinib to be well tolerated, with responses observed in NSCLC, colorectal cancer as early as 4 weeks after first treatment

* Ignyta Inc - studies showed entrectinib responses observed in NSCLC, colorectal cancer lasted as long as 2.5 years and still ongoing Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below